Pure Global
NCT06322394

BXOS110 Injection in the Treatment of Acute Ischaemic Stroke

A Multicentre, Randomised, Double-blind, Placebo-parallel Controlled Phase II Clinical Trial Evaluating the Efficacy and Safety of BXOS110 Injection in the Treatment of Acute Ischaemic Stroke Within 3 Hours of Onset
Biocells (Beijing) Biotech Co.,Ltd·Phase 2·ClinicalTrials.gov·drugRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Acute Ischemic Stroke
Drug/Device/Intervention
high-dose BXOS110
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Biocells (Beijing) Biotech Co.,Ltd
Location
Shaoguan,Hengshui,Shijiazhuang,Daqing,Anyang,Nanyang,Nanyang,Nanyang,Meihekou,Chaoyang,Fuxin,Shenyang,Shenyang,Shenyang,Tieling,Chifeng,Xianyang,Liaocheng,Linyi,Tengzhou,Datong,Linfen,Linfen,Beijing, China
Timeline & enrollment
Phase
Phase 2
Start date
Feb 07, 2024
End date
Sep 01, 2025
Enrollment
300 participants
Primary outcome

Proportion of subjects with mRS score 0-2 on day 90

Summary

The purpose of this study was to evaluate the effectiveness of early administration of
 BXOS110 for injection in reducing overall disability in patients with acute ischaemic stroke.

ICD-10 classifications
Stroke, not specified as haemorrhage or infarctionSequelae of stroke, not specified as haemorrhage or infarctionCerebral infarctionCerebral infarction, unspecifiedTransient cerebral ischaemic attack, unspecified
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06322394
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06322394 through Pure Global AI's free database. This Phase 2 trial is sponsored by Biocells (Beijing) Biotech Co.,Ltd and is currently Recruiting. The study focuses on Acute Ischemic Stroke. Target enrollment is 300 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.